Search Results for:

Alkem Subsidiary Enzene Launches Adalimumab Biosimilar in India

As reported by HealthCareRadius in India, on February 23, 2023, Enzene Biosciences, a subsidiary of Alkem Laboratories, announced commencement of commercial supplies of its biosimilar adalimumab (ENZ-129) in India to treat ankylosing spondylitis (AS) and rheumatoid arthritis (RA).  This is Enzene’s fourth biosimilar launch in the last eighteen months.  In…

Read More